Payment overview · 2025
General Payments
$3,434.58
89 reported records · 13 companies
Healthcare provider profile · identity verified
Vernis L. Beverly, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CHESAPEAKE, VA · NPI 1508821174
Verified facts
What the public records show
CMS Open Payments records show Vernis L. Beverly, M.D. received $3,434.58 in general payments during 2025 across 89 reported records.
AstraZeneca Pharmaceuticals LP accounted for 33.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Descovy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $1,157.71 | 33.7% | 27 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $864.36 | 25.2% | 22 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $552.11 | 16.1% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $250.05 | 7.3% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $175.80 | 5.1% | 4 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $145.32 | 4.2% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $102.40 | 3.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $63.82 | 1.9% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $31.22 | 0.9% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.40 | 0.9% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $26.12 | 0.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.63 | 0.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.64 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,434.58 | 89 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $552.11 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $381.54 | 9 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $380.56 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $359.58 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $293.30 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $250.05 | 10 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $124.93 | 1 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $120.75 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $102.03 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $88.78 | 1 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $76.51 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $70.26 | 4 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $68.81 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $50.87 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $41.53 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $31.22 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $29.40 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $29.40 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $26.12 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| BEVESPI AEROSPHERE Normalized: bevespi aerosphere |
Drug | AstraZeneca Pharmaceuticals LP | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.62 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 114 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 67 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 63 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
67 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 14 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
114 | 13 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
74 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 618 | 141 |
| Atorvastatin Calcium | Atorvastatin Calcium | 460 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 324 | 65 |
| Lisinopril | Lisinopril | 322 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 310 | 79 |
| Metoprolol Tartrate | Metoprolol Tartrate | 297 | 61 |
| Metformin Hcl | Metformin Hcl | 296 | 62 |
| Omeprazole | Omeprazole | 278 | 56 |
| Furosemide | Furosemide | 245 | 76 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 229 | 46 |
| Simvastatin | Simvastatin | 228 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 212 | 70 |
| Losartan Potassium | Losartan Potassium | 212 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 187 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 173 | 45 |
| Diclofenac Sodium | Diclofenac Sodium | 154 | 63 |
| Naproxen | Naproxen | 152 | 53 |
| Trazodone Hcl | Trazodone Hcl | 141 | 31 |
| Gabapentin | Gabapentin | 137 | 47 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 136 | 22 |
| Montelukast Sodium | Montelukast Sodium | 134 | 32 |
| Prednisone | Prednisone | 127 | 59 |
| Amitriptyline Hcl | Amitriptyline Hcl | 124 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 123 | 14 |
| Clonidine Hcl | Clonidine Hcl | 121 | 27 |
| Nifedipine Er | Nifedipine | 121 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 116 | 23 |
| Potassium Chloride | Potassium Chloride | 115 | 27 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 114 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 43 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 113 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 111 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 108 | 30 |
| Januvia | Sitagliptin Phosphate | 104 | 15 |
| Tramadol Hcl | Tramadol Hcl | 99 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 17 |
| Meloxicam | Meloxicam | 84 | 21 |
| Carvedilol | Carvedilol | 83 | 23 |
| Famotidine | Famotidine | 74 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 15 |
| Farxiga | Dapagliflozin Propanediol | 67 | 12 |
| Ibuprofen | Ibuprofen | 67 | 27 |
| Sertraline Hcl | Sertraline Hcl | 67 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 65 | 21 |
| Jardiance | Empagliflozin | 63 | 14 |
| Benztropine Mesylate | Benztropine Mesylate | 62 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 59 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 19 |
| Atenolol | Atenolol | 57 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 55 | 13 |
| Levetiracetam | Levetiracetam | 50 | 12 |
| Alprazolam | Alprazolam | 49 | 12 |
| Azithromycin | Azithromycin | 48 | 16 |
| Aripiprazole | Aripiprazole | 47 | suppressed |
| Eliquis | Apixaban | 47 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 47 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 47 | 25 |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 45 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 24 |
| Glipizide | Glipizide | 43 | 11 |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 39 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 13 |
| Allopurinol | Allopurinol | 36 | suppressed |
| Premarin | Estrogens, Conjugated | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Ezetimibe | Ezetimibe | 35 | suppressed |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Haloperidol | Haloperidol | 33 | suppressed |
| Colchicine | Colchicine | 32 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 32 | 11 |
| Finasteride | Finasteride | 32 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Nystatin | Nystatin | 31 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Risperidone | Risperidone | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 11 |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | 11 |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | 11 |
| Tivicay | Dolutegravir Sodium | 25 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 11 |
| Pregabalin | Pregabalin | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 21 |
| Indomethacin | Indomethacin | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Anastrozole | Anastrozole | 19 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Phenobarbital | Phenobarbital | 19 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 17 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Bumetanide | Bumetanide | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Emtricitabine | Emtricitabine | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Edurant | Rilpivirine Hcl | 12 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 12 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,434.58 · 89 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BEVESPI AEROSPHERE, BREZTRI, Biktarvy, CABENUVA, CAPLYTA, DOVATO, FARXIGA, JARDIANCE, MOUNJARO, NUZYRA, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SKYCLARYS, TEZSPIRE, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, XHANCE, Yeztugo, ZEPBOUND, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error